Dr. Moskowitz on the ALCANZA Trial in CTCL
4 Ansichten
• 08/09/23
0
0
Einbetten
administrator
Abonnenten
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
Zeig mehr
Facebook Kommentare
SORT BY-
Beste Kommentare
-
Neueste Kommentare